Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0916 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MK0916 | DRUG | - |
Inclusion Criteria: * Have Type 2 Diabetes * 18 to 65 years of age Exclusion Criteria: * History of Type 1 Diabetes Mellitus * Have been treated with insulin in the past 8 weeks * On a weight loss program and have ongoing weight loss * Taking weight loss medication * Have had surgery requiring ge...
MK0916 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus and metabolic syndrome. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
MK0916 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 diabetes and metabolic syndrome.
MK0916 is in Phase 2 clinical development. It is an investigational drug and has not received regulatory approval. One Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
MK0916 has been studied in one completed Phase 2 clinical trial, identified as NCT00543595. This trial enrolled 154 participants with Type 2 Diabetes Mellitus and metabolic syndrome, and it was a randomized, double-blind study.
MK0916 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus and metabolic syndrome. The drug has completed one clinical trial but has not yet been approved for commercial use.